Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
In this trial, 261 patients with chronic thromboembolic pulmonary hypertension were assigned to placebo or to the soluble guanylate cyclase stimulator riociguat. At 16 weeks, riociguat had significantly improved the 6-minute walk distance and pulmonary vascular resistance. Chronic thromboembolic pul...
Saved in:
Published in | The New England journal of medicine Vol. 369; no. 4; pp. 319 - 329 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Waltham, MA
Massachusetts Medical Society
25.07.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!